Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

被引：0
|
作者：
Buecklein, Veit L. [1 ]
Ayuk, Francis A. [2 ]
Holderried, Tobias A. W. [3 ]
Mai, Christine [4 ]
Kievit, Bradley [5 ]
Blisset, Rob [5 ]
Doble, Brett [6 ]
Reid, Geoff [6 ]
Reimeir, Laura [7 ]
Bruns, Caroline [7 ]
Vadgama, Sachin [6 ]
机构：
[1] LMU Univ Hosp, Dept Med 3, Munich, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany
[3] Univ klinikum Bonn UKB, Bonn, Germany
[4] AplusA, Lyon, France
[5] Maple Hlth Grp LLC, New York, NY USA
[6] Gilead Co, Kite, Santa Monica, CA USA
[7] Gilead Sci GmbH, Munich, Germany
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-205589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5037 / 5038
页数：2
相关论文
共 50 条
  • [31] Modified R-DAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Rigacci, L.
    Fabbri, A.
    Mappa, S.
    Nassi, L.
    Lenoci, M.
    Puccini, B.
    Alterini, R.
    Chitarrelli, I
    Carrai, V
    Lauria, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 61 - 61
  • [32] Modified R-DHAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Fabbri, A.
    Rigacci, L.
    Lenoci, M.
    Mappa, S.
    Puccini, B.
    Nassi, L.
    Chitarrelli, I.
    Gozzetti, A.
    Alterini, R.
    Carrai, V.
    Bosi, A.
    Lauria, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 219 - 220
  • [33] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [34] Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Yung, Mallory
    Schnell, Frederick
    Vukcevic, Mirko
    Kurukulasuriya, Nuwan C.
    BLOOD, 2021, 138 : 1928 - +
  • [35] Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients
    Veeraputhiran, Muthu
    Mehta, Amitkumar
    Alencar, Alvaro J.
    Modi, Dipenkumar
    Voorhees, Timothy J.
    Narkhede, Mayur
    BLOOD, 2022, 140 : 12089 - 12091
  • [36] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [37] L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
    Duell, Johannes
    Jurczak, Wojciech
    Liberati, Anna Marina
    Halka, Janusz
    Carbo, Esther Pena
    Costa, Pau Abrisqueta
    Maddocks, Kami J.
    Dreyling, Martin
    Rosenwald, Andreas
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    BLOOD, 2022, 140 : 6596 - 6598
  • [38] A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
    Hayashino, K.
    Nishimori, H.
    Fujiwara, K.
    Kondo, K.
    Matsubara, C.
    Terao, T.
    Kitamura, W.
    Kamoi, C.
    Seike, K.
    Fujiwara, H.
    Asada, N.
    Ennishi, D.
    Fujii, K.
    Fujii, N.
    Matsuoka, K-I.
    Maeda, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1602 - S1603
  • [39] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
    Hutchings, M.
    Dickinson, M.
    Carlo-Stella, C.
    Morschhauser, F.
    Bachy, E.
    Corradini, P.
    Iacoboni, G.
    Khan, C.
    Wrobel, T.
    Offner, F.
    Trneny, M.
    Wu, S. -J.
    Cartron, G.
    Hertzberg, M.
    Sureda, A.
    Perez-Callejo, D.
    Lundberg, L.
    Relf, J.
    Clark, E.
    Humphrey, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
  • [40] TREATMENT PREFERENCES AMONG PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN FRANCE, GERMANY, ITALY, JAPAN, SPAIN, THE UNITED STATES, AND THE UNITED KINGDOM
    Michaels-Igbokwe, C.
    Collacott, H.
    Clarke, H.
    Liu, F. F.
    VALUE IN HEALTH, 2023, 26 (12) : S495 - S495
12345